JT

Jim Trenkle

Partner, Venture Investments at Novo Holdings

San Francisco, California

Overview 

Jim Trenkle is a Partner in Venture Investments at Novo Holdings in San Francisco, with a background in drug development and clinical trials. He has successfully invested in companies like MapLight Therapeutics and ROME Therapeutics, focusing on sectors such as Pharmaceuticals and Biotechnology. Trenkle's career highlights include holding leadership roles at Sanofi and Pivotal bioVenture Partners, as well as contributing to the growth and success of various startups in the medical and biotech industries through strategic investments.

Work Experience 

  • Partner, Venture Investments

    2022 - Current

  • Head of Investments, Sanofi Ventures

    2020 - 2022

    Board Member: Therini Bio, Glycomine, Rome Therapeutics, Veralox and Stealth Newco

  • Vice President

    2017 - 2020

    Board observer for Bolt Bio (BOLT), Inozyme (INZY), Karuna Pharma (KRTX), Fusion Pharma (FSUN) and Akouos (AKUS)

  • Associate Director, Commercial Planning Liver Disease

    2016 - 2017

    Pipeline Marketing Sciences for Hepatitis C and Liver Fibrosis Market research and forecasting for pipeline, inline, and external opportunity assets

  • Associate Director, Liver Disease Project and Portfolio Management

    2014 - 2016

    Expanding levels of responsibility and impact in each year, with Global Development strategy and execution responsibility for: • Complete Hepatitis C portfolio, including Sovaldi, Harvoni, SOF/VEL, and SOF/VEL/GS-9857 • Responsible for an aligned Liver Fibrosis company strategy. • Manage cross-functional teams and subteams: Clinical Research, Commercial Strategy, Clinical Operations, Regulatory Affairs, Process Chemistry and Manufacturing, and Medical Affairs

  • Sr Manager, Liver Disease Project and Portfolio Management

    2010 - 2013

    Managed ledipasvir and other hepatitis C compounds through development.

  • Research Scientist I/II, Medicinal Chemistry

    2007 - 2010

    Proven scientist with increasing title and responsibilities during my time in Research, with multiple successes in different therapeutic areas. • Three new chemical entities advanced into HCV clinical development. Two NCEs in Phase 2, one in Phase 3. One program in HIV advanced into clinic. • Collaborated heavily with biology, DMPK, structural chemistry, and formulation colleagues • Managed one direct report • Departmental ambassador

Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.

Raised $4,413,500,000.00 from Abingworth.

  • Graduate Research Assistant, Chemistry

    2002 - 2007

    PhD with Professor Tim Jamison in Organic Synthetic Chemistry. Single person total synthesis of complex natural product, the macrolide (–)-gloeosporone. Focus on organonickel, organocopper, alkyne, and epoxide chemistry.

  • Medicinal Chemistry Research Internship

    2002 - 2002

Pfizer is a biopharmaceutical company that provides affordable access to safe, effective medicines and health care services.

Raised $32,000,000,000.00 from Starboard Value.

Articles About Jim

Relevant Websites